Paclitaxel liposomal

Drug Profile

Paclitaxel liposomal

Alternative Names: EndoTAG-1; MBT-0206; SB 05

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator University of California at San Francisco
  • Developer Jules Bordet Institute; MediGene AG; SynCore Biotechnology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase III Breast cancer
  • No development reported Colorectal cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 19 Apr 2017 SynCore Biotechnology plans a phase III trial for Pancreatic cancer (Late-stage disease, Second-line therapy or greater, Combination therapy, Metastatic disease) (NCT03126435)
  • 01 Nov 2016 Phase-III clinical trials in Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in Taiwan (IV) (NCT03002103)
  • 28 Mar 2016 Syncore Biotechnology acquires ENDOTAG® technology from Medigene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top